The US weight loss drug industry is booming, with an estimated $50 billion annual market size. Companies are battling over who gets to manufacture these medications, which have been found to greatly benefit people with type 2 diabetes and obesity.
Bruce Cohen, a Boca Raton resident, credits a new anti-diabetic medication called Ozempics for transforming his life. He lost 100 pounds after taking the drug, but struggled to find it when he needed a refill. Other Americans are experiencing similar shortages due to high demand.
Dr. Jessica Chen, co-founder of ThriveWell, explains that compound pharmacies can now produce these medications at a lower cost, allowing more people access them. However, some pharmaceutical companies are pushing back against this trend, citing safety concerns and the need for FDA approval.
The American Diabetes Association shares these concerns, while the Alliance for Pharmacy Compounding argues that these drugs are safe when produced in a regulated environment. As the demand for anti-obesity medications continues to grow, Americans are left navigating this complex landscape of healthcare and consumer choice.
The government’s stance on this issue may also shift with new leadership in Washington. HHS Secretary nominee RFK Jr. has expressed support for lifestyle changes as the first line of defense against obesity, but also believes these medications can be effective when affordable. As the shortage continues to spark debate, consumers are left to weigh their options and consider alternative solutions.
Source: https://cbs12.com/news/local/the-battle-over-anti-obesity-medications-ozempics-weightloss-diabetes-thrivewell-eli-lilly-february-7-2025